SCHEMBL8339280

SCHEMBL8339280

CCN1CCC[C@@H]1C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HRH1 P35367 3/20 0.42
MEN1 O00255 1/20 0.42
CYP2D6 P10635 1/20 0.42
SCN1A P35498 1/20 0.42
KMT2A Q03164 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
CHRM3 P20309 2/20 0.42
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DUT P33316 4/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8336619 1.00 LMNA (0.56) LMNAATML3MBTL1HRH1MEN1
SCHEMBL8336623 1.00 LMNA (0.56) LMNAATML3MBTL1HRH1MEN1
SCHEMBL10123845 0.95 LMNA (0.51) LMNAATML3MBTL1HRH1MEN1
SCHEMBL8342637 0.88 LMNA (0.53) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL8339348 0.88 LMNA (0.53) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL8343216 0.88 LMNA (0.53) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL8477474 0.85 LMNA (0.51) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL8477470 0.85 LMNA (0.51) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL8481946 0.85 LMNA (0.51) LMNAATML3MBTL1HRH1CHRM3
SCHEMBL20600129 0.84 ATM (0.51) LMNAATML3MBTL1HRH1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5925666-A DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING GUILFORD PHARMACEUTICALS INC. (US) 1999-07-20 US claimed
WO-1999003467-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE DISORDERS USING PYRROLIDINE DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1999-01-28 WO claimed
US-5925666-A DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING GUILFORD PHARMACEUTICALS INC. (US) 1999-07-20 US disclosed
WO-1999003467-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING COMPULSIVE DISORDERS USING PYRROLIDINE DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1999-01-28 WO disclosed
US-5650521-A FOR TREATING COCAINE ADDICTION AND OVERDOSE, AND DISEASES AND CONDITIONS CHARACTERIZED BY ABNORNAL DOPAMINERGIC NEUROTRANSMISSION GUILFORD PHARMACEUTICALS INC. (US) 1997-07-22 US disclosed